Die rasante Entwicklung der Diabetesforschung hat viele neue Medikamente und Therapiestrategien auf den Weg gebracht, die das Potenzial haben, auch unabhängig von einer Diabeteserkrankung wirksam zu sein. So gibt es neue Erkenntnisse zu SGLT-2-Inhibitoren bei Herz- und chronischer Niereninsuffizienz. Auch die Weiterentwicklung inkretinbasierter Medikamente und duale GIP/GLP-1-Rezeptoragonisten sind vielversprechend.
Abstract
Diabetes mellitus has become a widespread disease worldwide. In recent years, there has been a rapid development of therapeutic options in the field of diabetology. Many new drugs and therapeutic strategies are now available or will be available in the near future, which have the potential to significantly improve the care of patients even if they do not have diabetes. In this article, we would like to present the latest therapeutic options and possible further applications. The article focuses, among other things, on the new findings of SGLT-2-inhibitors in cardiac and chronic renal failure and the further development of incretin-based drugs toward dual GIP/GLP-1-receptor agonists. Once-weekly insulin and the selective mineralocorticoid receptor antagonist finerenone will also be presented.
Schlüsselwörter
Diabetes mellitus Typ 2 - GLP-1- Rezeptoragonisten - SGLT-2-Inhibitoren - Insulin Icodec - Finerenon
Key words
type 2 diabetes mellitus - GLP-1 receptor agonist - SGLT-2-inhibitors - insulin icodec - finerenone
